ASX:CSLBiotechs
CSL (ASX:CSL) Trailing Net Margin Compression Tests Bullish Growth Narratives
CSL (ASX:CSL) has put out its H1 2026 numbers with the latest trailing 12 month snapshot showing revenue of about US$15.4b and basic EPS of US$2.89, while headline metrics for the last reported half year include H2 2025 revenue of US$7.1b and basic EPS of US$2.05. Over recent periods, the company has seen revenue move from US$6.7b in H2 2024 to US$8.5b in H1 2025 and then US$7.1b in H2 2025, alongside EPS shifting from US$1.53 to US$4.15 and then US$2.05. This sets a mixed earnings tape that...